Breaking News Instant updates and real-time market news.

MDT

Medtronic

, DG

Dollar General

09:40
11/22/16
11/22
09:40
11/22/16
09:40

Unusually active option classes on open November 22nd

Unusual total active option classes on open include: Medtronic (MDT), Dollar General (DG), Cliffs Natural (CLF), Market Vectors Oil Services (OIH), Intel (INTC), MetLife (MET), United States Oil Fund (USO), Amazon (AMZN), Celgene (CELG), and JPMorgan (JPM).

MDT

Medtronic

DG

Dollar General

CLF

Cliffs Natural

OIH

Oil Services Holders Trust

INTC

Intel

$34.98

0.03 (0.09%)

MET

MetLife

USO

United States Oil Fund

AMZN

Amazon.com

$780.00

19.84 (2.61%)

CELG

Celgene

$124.16

2.19 (1.80%)

JPM

JPMorgan

  • 22

    Nov

  • 22

    Nov

  • 28

    Nov

  • 01

    Dec

  • 04

    Dec

  • 06

    Dec

  • 16

    Dec

  • 13

    Jan

  • 28

    Feb

  • 14

    Jul

  • 12

    Oct

MDT Medtronic

11/15/16
LEER
11/15/16
NO CHANGE
LEER
Edwards Lifesciences, Medtronic selloff overdone, says Leerink
Leerink analyst Danielle Antalffy notes that both Edwards Lifesciences (EW) and Medtronic (MDT) traded down in reaction to a presentation of the German Aortic Valve Registry data in intermediate risk patients. However, she believes the selloff is overdone, with no change to her estimated total addressable transcatheter aortic valve replacement, or TAVR, market opportunity as there are key baseline characteristic differences between both the surgical valve and TAVR groups that skews the data, and randomized controlled clinical trial data trumps registry data.
11/14/16
EVER
11/14/16
NO CHANGE
EVER
Medtronic, Edwards Lifesciences defended at Evercore ISI
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Overweight
Piper would buy TAVR names on 'GARY' registry weakness
Piper Jaffray analyst Brooks West attributes today's weakness in transcatheter aortic valve replacement makers Medtronic (MDT), Edwards Lifesciences (EW) and Boston Scientific (BSX) to a presentation at the AHA meeting of data from the German Aortic Valve Registry, or "GARY," comparing one year outcomes for patients at intermediate surgical risk who underwent isolated interventional versus conventional surgical aortic valve replacement for severe symptomatic aortic valve stenosis. The data showed a surprisingly negative result, but prior debates around the "GARY" led to no impact on TAVR volumes and West is "skeptical of the results," he tells investors. The firm has Overweight ratings on all three stocks mentioned above.
11/02/16
BMOC
11/02/16
NO CHANGE
BMOC
Dexcom still has positive catalysts, says BMO Capital
After Dexcom reported higher than expected Q3 revenue but said it does not expect its 2016 revenue to come in above its previous guidance range, BMO Capital analyst Joanne Wuensch says that the company's Q4 and 2017 results will probably be negatively impacted by Medtronic's (MDT) upcoming MiniMed 670G product. Nonetheless, the analyst says that the pending non-adjunctive label for Dexcom's CGM "can make waves," while it has "ample" room for growth in its "vastly underserved" market, as its "technology is nowhere near its full potential." The analyst cut her price target on the shares to $90 from $112 but keeps an Outperform rating on the stock.
DG Dollar General

10/04/16
CLVD
10/04/16
NO CHANGE
CLVD
Dollar General Q3 comps trending below consensus, says Cleveland Research
Cleveland Research said Dollar General's Q3 are likely trending below consensus driven by continued competitive headwinds. The firm's analyst said Dollar General appears to ramping up promotional/price aggressiveness in order to drive a recovery and sees risk to near-term margin and sales consensus expectations.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/16
KEYB
10/12/16
INITIATION
KEYB
Sector Weight
Dollar General initiated with a Sector Weight at KeyBanc
KeyBanc analyst Bradley Thomas initiated Dollar General with a Sector Weight saying consensus estimates still need to move down and looks to get more positive on further shares weakness.
10/13/16
10/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Buy at Jefferies. 2. eBay (EBAY) and Etsy (ETSY) coverage assumed with a Neutral at Wedbush. 3. Five Below (FIVE) and Dollar Tree (DLTR) were initiated with an Overweight at KeyBanc while the firm initiated Dollar General (DG) with a Sector Weight. 4. Baxter (BAX) initiated with an Outperform at Wells Fargo. 5. Symantec (SYMC) initiated with an Outperform at FBN Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CLF Cliffs Natural

10/07/16
FBCO
10/07/16
INITIATION
Target $2
FBCO
Underperform
Cliffs Natural reinstated with an Underperform at Credit Suisse
Credit Suisse analyst Curt Woodworth reinstated Cliffs Natural with an Underperform and a $2 price target primarily due to a bearish view on iron ore.
07/12/16
JPMS
07/12/16
NO CHANGE
Target $10.5
JPMS
Overweight
Cliffs Natural price target raised to $10.50 from $7 at JPMorgan
JPMorgan analyst Michael Gambardella raised his price target for Cliffs Natural Resources to $10.50 and keeps an Overweight rating on the name. The recent bankruptcy of Essar Steel Minnesota has further solidified Cliffs' "defensible business model," Gambardella tells investors in a research note. The short interest in the name, at 43% of outstanding float, is "extremely high despite the wave of positive developments," the analyst contends. He sees a likely positive catalyst from near-term earnings beats amid higher steel pricing.
07/18/16
CLKS
07/18/16
UPGRADE
CLKS
Neutral
Cliffs Natural upgraded to Neutral from Sell at Clarksons Platou
11/14/16
MSCO
11/14/16
UPGRADE
Target $9
MSCO
Equal Weight
Cliffs Natural upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Evan Kurtz upgraded Cliffs Natural to Equal Weight and raised its price target to $9 from $3. The analyst believes the Trump victory has led to the first "credible long-term investment case" for steel equities for the first time in a decade and expects Trump's proposals for infrastructure spending and trade protection to add to demand and curb import supply. Kurtz said Cliffs is leveraged to HRC steel prices ad will benefit from higher blast furnace operating rates.
OIH Oil Services Holders Trust

INTC Intel
$34.98

0.03 (0.09%)

11/22/16
MKMP
11/22/16
NO CHANGE
MKMP
Buy
MKM Partners raises NVIDIA, AMD price targets on inflecting semi opportunities
MKM Partners analyst Ian Ing raised his price target for NVIDIA (NVDA) to $106 from $87, saying that thematic attention is heating up as large suppliers are crowding into artificial intelligence as an investment theme with non-GPU solutions. While other suppliers may be able to come up with better performance-for-power in certain use cases, he believes NVIDIA GPUs still have user stickiness with developer incumbency and easy-to-use tools that will be difficult to overcome. The analyst also raised his price target for AMD (AMD) to $10.50 from $8 to reflect improved prospects for the company driven by new product pipeline. Although Ian expects AMD to be a relatively minor player, its shares are helped by continued A.I. headlines and NVIDIA, Intel (INTC), and Qualcomm (QCOM) turning increasingly vocal on the opportunity. He reiterates a Buy rating on NVIDIA and AMD shares.
10/19/16
PACS
10/19/16
NO CHANGE
PACS
Intel Q4 PC commentary negative for Marvell, others resilient says Pacific Crest
Pacific Crest notes that Intel (INTC) said its PC customers are poised to reduce their inventories in Q4. The firm says that the comment is negative for Marvell (MRVL). However, the firm believes that Advanced Micro Devices (AMD), NVIDIA (NVDA), ON Semiconductor (ON) and Synaptics (SYNA) are "most resilient" to this development, given their share gains, growth and other factors.
10/19/16
PACS
10/19/16
NO CHANGE
PACS
Intel data center results bode badly for several stocks, says Pacific Crest
Pacific Crest says that Intel's (INTC) data center results and commentary were "modestly disappointing," as enterprise demand for the company's data center products was "weak," according to the firm. The firm thinks that the negative enterprise results are "modestly negative for stocks with enterprise exposure, including Micron (MU), Seagate (STX) and Western Digital (WDC)."
10/19/16
ROTH
10/19/16
NO CHANGE
Target $40
ROTH
Buy
Roth Capital cuts Intel price target after guidance disappoints
Roth Capital analyst Suji Desilva lowered his price target for Intel to $40 from $43 after disappointing guidance. However, the analyst expects the shares to recover with a reset of expectations. Desilva continues to be encouraged by the company's transition to growth areas such as cloud data center, networking and IoT, and by the stable margin profile. He reiterates a Buy rating on the shares.
MET MetLife

10/07/16
FBCO
10/07/16
INITIATION
Target $51
FBCO
Neutral
MetLife initiated with a Neutral at Credit Suisse
Credit Suisse analyst John Nadel initiated MetLife with a Neutral and a $51 price target.
07/13/16
07/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yelp (YELP) downgraded to Underperform from Market Perform at Wells Fargo with analyst Peter Stabler saying consensus expectations "embed too much optimism" for 2017 and 2018. 2. Starbucks (SBUX) downgraded to Mixed from Positive at OTR Global with the firm citing manager checks that indicate weaker-than-expected food and Frappuccino sales, impact from poor weather, and cannibalization. 3. SQM (SQM) downgraded to Sell from Neutral at Citi analyst Juan Tavarez saying the risk/reward is unfavorable with the stock up 42% year-to-date. 4. Robert Half (RHI) downgraded to Neutral from Buy at BofA/Merrill with the firm citing expectations of weaker fundamentals, FX headwinds, and increased concerns around the timing of the cycle. 5. MetLife (MET) downgraded to Hold from Buy at Deutsche Bank with analyst Yaron Kinar saying balance sheet risk is enhanced ahead of the company's separation and in light of low yields. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/16
WELS
09/22/16
INITIATION
WELS
Outperform
MetLife coverage resumed with an Outperform at Wells Fargo
09/23/16
WELS
09/23/16
INITIATION
WELS
Outperform
MetLife coverage resumed at Wells Fargo
As noted earlier, Wells Fargo resumed coverage of MetLife with an Outperform rating. The firm says that , in the wake of the company's decision to separate its retail business, it "should be less impacted by equity market movement and interest rates." As a result, the firm thinks that the stock's multiple should rise, while the company should require less capital, enabling it to buy back its shares. Wells set a $51-$53 price target on the stock.
USO United States Oil Fund

AMZN Amazon.com
$780.00

19.84 (2.61%)

11/17/16
PIPR
11/17/16
NO CHANGE
PIPR
Piper sees Trump-related Internet selloff as 'rare opportunity'
Piper Jaffray analyst Gene Munster says he would be "buying the fear" priced into Internet mega-caps. Concerns of President-Elect Trump's impact on tech companies are being largely extrapolated from sound bites that are unlikely to manifest during Trump's presidency, Munster tells investors in a research note. The selloff in "best-in-class" large cap internet stocks Apple (AAPL), Amazon.com (AMZN), Alphabet (GOOG), Facebook (FB) and Netflix (NFLX) presents a "rare opportunity," Munster writes. He believes Trump's threats towards Amazon are without merit and that net neutrality is unlikely to be reversed. He finds the valuations for each of the mega-caps "very attractive."
11/21/16
SBSH
11/21/16
NO CHANGE
Target $16
SBSH
Buy
Citi fields Pandora questions after Amazon on-demand launch
Citi analyst Mark Kelley says he's received a lot of questions from investors over the last few days on the impact from potentially lower prices for Pandora's (P) on-demand offering after Amazon (AMZN) launched a competing service. Amazon's on-demand offering costs $7.99 per month for Prime users, or $3.99 if you only want to listen on your echo device. Non-Prime users must pay $9.99 per month. The launch by Amazon has caused some speculation in the press that Apple (AAPL) is going to lower its prices, Kelley tells investors in a research note. The analyst does not expect Pandora to lower the price of on-demand to $7.99 per month. Kelley still believes on-demand music is the way the industry moves forward and he remains bullish on Pandora's long-term opportunity. The analyst has a Buy rating on the shares with a $16 price target.
11/21/16
BARD
11/21/16
NO CHANGE
BARD
Outperform
Baird expects Amazon.com distribution announcement with Patterson
Following industry conversions, Baird analyst Jeff Johnson expects Patterson Companies (PDCO) to announce an Amazon.com (AMZN) distribution agreement tomorrow. What the analyst hadnt considered and is now hearing is that Amazon could fulfill orders placed through Patterson's order portal, lowering Patterson's fulfillment costs and given the company breathing room as it pursues DSO deals. Johnson rates Patterson a Neutral with a $48 price target.
11/18/16
OPCO
11/18/16
NO CHANGE
OPCO
Public cloud infrastructure market will be $62B by 2020, says Oppenheimer
Oppenheimer analyst Timothy Horan says "the race is on" for public cloud providers to get as much of their customers' data on their respective cloud platforms as possible. The analyst believes Amazon (AMZN) Web Services, Microsoft (MSFT), and Alphabet's Google (GOOG; GOOGL) have ambitions to become the dominant OS of the cloud, and to do so these companies will aim to have integrated solutions from the infrastructure layer to services through first-party offerings and/or the development of a strong partner channel. He views AWS as the primary wholesale cloud platform and Microsoft as the enterprise platform. However, given the relative immaturity of the market and the massive $1T opportunity, all three have been successful focusing on multiple segments, Horan adds, noting that he expects the public cloud infrastructure market to be $62B by 2020.
CELG Celgene
$124.16

2.19 (1.80%)

11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/09/16
STPT
11/09/16
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
JPM JPMorgan

11/09/16
11/09/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) downgraded to Neutral from Outperform at Baird with analyst David George noting the stock's outperformance and the higher re-rating of its valuation multiple. 2. GoPro (GPRO) downgraded to Neutral from Outperform at Wedbush, to Market Perform from Outperform at Raymond James, and to Sell from Neutral at Dougherty. 3. Universal Health (UHS) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Mizuho, and to Market Perform from Outperform at Avondale. 4. Globus Medical (GMED) downgraded to Market Perform from Outperform at JMP Securities, to Perform from Outperform at Oppenheimer, and to Market Perform from Outperform at William Blair. 5. Delphi (DLPH) and Magna (MGA) were downgraded to Underperform from Buy at BofA/Merrill while the firm downgraded Lear (LEA), American Axle (AXL), Adient (ADNT), and BorgWarner (BWA) to Underperform from Neutral. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/11/16
RBCM
11/11/16
NO CHANGE
RBCM
Banks to benefit from higher interest rates, says RBC Capital
RBC Capital believes that the Fed is committed to raising interest rates, and it expects FOMC members' forecast to show they expect two rate increases to occur in 2017. The firm expects higher rates to boost banks' net interest margin, raising their profits. It identifies Bank of America (BAC), JPMorgan (JPM), Citizens Financial (CFG),M&T Bank (MTB), and Regions Financial (RF) as being among the banks most likely to benefit from short-term rate increases.
11/18/16
11/18/16
INITIATION
Target $65

Underweight
American Express initiated with an Underweight at Stephens
As previously reported, Stephens analyst started American Express (AXP) with an Underweight rating and $65 price target, citing rising rates, shrinking markets as American Express ramps up rewards to maintain share, and the risk to 2017 EPS guidance. The analyst expects competition from bank peers, such as JPMorgan (JPM) and Citi (C), to continue to pressure American Express' earnings.
11/09/16
BARD
11/09/16
DOWNGRADE
Target $72
BARD
Neutral
JPMorgan downgraded to Neutral at Baird
As reported previously, Baird analyst David George downgraded JPMorgan to Neutral from Outperform. The analyst noted its outperformance and the higher re-rating of its valuation multiple. George believes investors should reduce their risk heading into a potential interest rate hike. He maintained his $72 price target on JPMorgan shares.

TODAY'S FREE FLY STORIES

ABT

Abbott

$39.00

0.32 (0.83%)

10:26
12/09/16
12/09
10:26
12/09/16
10:26
Hot Stocks
Abbott raises quarterly dividend to 26.5c from 26c »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCOM

Hawaiian Telcom

$23.87

0.74 (3.20%)

10:26
12/09/16
12/09
10:26
12/09/16
10:26
Conference/Events
Hawaiian Telcom management to meet with Drexel Hamilton »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 14

    Dec

  • 15

    Dec

AZN

AstraZeneca

$27.11

0.84 (3.20%)

10:26
12/09/16
12/09
10:26
12/09/16
10:26
Hot Stocks
Breaking Hot Stocks news story on AstraZeneca »

AstraZeneca trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

AZN

AstraZeneca

$27.11

0.84 (3.20%)

10:25
12/09/16
12/09
10:25
12/09/16
10:25
Hot Stocks
Breaking Hot Stocks news story on AstraZeneca »

AstraZeneca trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

ATH

Athene Holding

10:25
12/09/16
12/09
10:25
12/09/16
10:25
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

10:25
12/09/16
12/09
10:25
12/09/16
10:25
General news
The U.S. wholesale report beat estimates »

The U.S. wholesale report…

PSTG

Pure Storage

$12.26

-0.075 (-0.61%)

10:25
12/09/16
12/09
10:25
12/09/16
10:25
Conference/Events
Pure Storage participates in a conference call with UBS »

UBS IT Hardware & EMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

MEET

MeetMe

$5.47

0.28 (5.40%)

10:24
12/09/16
12/09
10:24
12/09/16
10:24
Conference/Events
MeetMe management to meet with Roth Capital »

Meeting to be held in St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DATA

Tableau

$45.85

0.2 (0.44%)

10:24
12/09/16
12/09
10:24
12/09/16
10:24
Rumors
Rumor moving shares of Tableau »

Rumor: Tableau moves up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ATH

Athene Holding

10:23
12/09/16
12/09
10:23
12/09/16
10:23
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ICHR

Ichor Holdings

10:23
12/09/16
12/09
10:23
12/09/16
10:23
Syndicate
Ichor Holdings indicated to open at $9.75, IPO priced at $9.00 »

Ichor Holdings (ICHR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CPB

Campbell Soup

$59.00

0.72 (1.24%)

10:21
12/09/16
12/09
10:21
12/09/16
10:21
Options
Campbell Soup calls are stirring »

Campbell Soup calls are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

Restoration Hardware

$32.75

-6.24 (-16.00%)

10:20
12/09/16
12/09
10:20
12/09/16
10:20
Options
Restoration Hardware options active as shares fall on earnings »

Restoration Hardware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

10:20
12/09/16
12/09
10:20
12/09/16
10:20
General news
Treasury Action: yields remained subdued »

Treasury Action: yields…

CPK

Chesapeake Utilities

$68.55

0.55 (0.81%)

, CNX

CONSOL

$21.16

-0.62 (-2.85%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

CPK

Chesapeake Utilities

$68.55

0.55 (0.81%)

CNX

CONSOL

$21.16

-0.62 (-2.85%)

JCI

Johnson Controls

$43.68

0.03 (0.07%)

AMID

American Midstream Partners

$16.95

-0.05 (-0.29%)

BIP

Brookfield Infrastructure

$32.93

0.2499 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ANF

Abercrombie & Fitch

$15.96

-0.28 (-1.72%)

, DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

ANF

Abercrombie & Fitch

$15.96

-0.28 (-1.72%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

HLT

Hilton

$26.54

0.295 (1.12%)

HZNP

Horizon Pharma

$15.03

-4.36 (-22.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 14

    Dec

AZN

AstraZeneca

$27.11

0.84 (3.20%)

, ADSK

Autodesk

$81.74

1.4 (1.74%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

AZN

AstraZeneca

$27.11

0.84 (3.20%)

ADSK

Autodesk

$81.74

1.4 (1.74%)

ETN

Eaton

$69.45

0.47 (0.68%)

FLR

Fluor

$56.77

0.77 (1.38%)

SYY

Sysco

$54.46

0.13 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 16

    Feb

$NYE

NYSE Market Internals

10:16
12/09/16
12/09
10:16
12/09/16
10:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

10:16
12/09/16
12/09
10:16
12/09/16
10:16
Technical Analysis
NASDAQ market internals summary »

Volume is light for this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATH

Athene Holding

10:15
12/09/16
12/09
10:15
12/09/16
10:15
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

10:15
12/09/16
12/09
10:15
12/09/16
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

SDRL

Seadrill

$3.72

0.315 (9.26%)

10:14
12/09/16
12/09
10:14
12/09/16
10:14
Options
Seadrill calls active as shares rally »

Seadrill calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHC

VirnetX

$3.35

0.05 (1.52%)

10:12
12/09/16
12/09
10:12
12/09/16
10:12
Periodicals
Breaking Periodicals news story on VirnetX »

Appeals court affirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATH

Athene Holding

10:10
12/09/16
12/09
10:10
12/09/16
10:10
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

XLF

Financial Select Sector

$23.63

-0.07 (-0.30%)

10:10
12/09/16
12/09
10:10
12/09/16
10:10
Options
$15.9M premium block in SPDR Financials »

$15.9M premium block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.